海外の治験の状況「前立腺癌」での検索結果
161件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not recruiting
- Radiotherapy - Adjuvant Versus Early Salvage
- Prostate Cancer;Prostate Cancer;Prostate Cancer;Prostate Cancer
- Australia, New Zealand
- 2009-03-10
Not Recruiting
- Measurement of variation in imaging report findings for 68Ga-PSMA-11 PET/CT in patients with prostate cancer: an international study with participation of multiple centers
- Prostate cancer br>Cancer
- Australia, Austria, Denmark, France, Germany, Japan, United States of America
- 2016-10-27
Authorised
- The aim of the study is to see if a new drug, enzalutamide, can improve outcomes for patients with metastatic prostate cancer compared with current treatment.This is a randomised controlled study trial which means that half the participants on the trial study will get enzalutamide and the other half will get current standard of care. All participants will receive active treatment for their cancer.
- Metastatic Prostate Cancer br>MedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Canada, France, Ireland, New Zealand, Poland, United Kingdom, United States
- 2014-11-21
Not Recruiting
- AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-COntrolled Efficacy and Safety Study of Oral MDV3100 in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
- Castration-Resistant Prostate Cancer;C61 - Malignant neoplasm of prostate
- Argentina, Australia, Austria, Belgium, Canada, Chile, France, Germany, Italy, Netherlands, Poland, South Africa, Spain, United Kingdom, United States
- 2014-04-14
Not recruiting
- Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
- Metastatic Castrate Resistant Prostate Cancer
- Austria, Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Czechia, Denmark, France, Germany, Hungary, Italy, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Turkey, United Kingdom, United States
- 2014-04-09
Not recruiting
- Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
- Prostate Cancer Metastatic
- Austria, Belgium, Czechia, France, Germany, Greece, Iceland, Ireland, Italy, Netherlands, Norway, Spain, United Kingdom
- 2015-06-26
Not Recruiting
- A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
- Prostate Cancer;C61 - Malignant neoplasm of prostate
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Estonia, France, Germany, Greece, India, Israel, Italy, Korea, Republic of, Latvia, Lebanon, Lithuania, Mexico, Netherlands, New Zealand, Panama, Peru, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, Province of China, Turkey, Ukraine, United Kingdom, United States
- 2015-04-30
Recruiting
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer
- Prostatic Neoplasms;C61 - Malignant neoplasm of prostate
- Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Japan, Korea, Republic of, Netherlands, New Zealand, Norway, Poland, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, Province of China, United Kingdom, United States
- 2015-04-29
Not Recruiting
- A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF ODM-201 IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- -C61 Malignant neoplasm of prostate Malignant neoplasm of prostate;Malignant neoplasm of prostate
- Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Finland, France, Germany, Greece, Hungary, Israel, Italy, Korea South, Latvia, Netherlands, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kindgdom, United States
- 2015-04-29
Recruiting
- An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 2010112, Given Once Daily by Subcutaneous Administration or by Continuous Intravenous Infusion, in Subjects With Castration-resistant Prostate Cancer
- Prostatic Neoplasms;C61 - Malignant neoplasm of prostate
- Austria, Germany
- 2015-04-17